Gilder Gagnon Howe & Co’s Vor Biopharma VOR Stock Holding History

Gilder Gagnon Howe & Co’s Portfolio VOR Stock Details VOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-3,159	Closed	-$734K	–	352
2021 Q4	$734K	Sell	3,159 -2,353	-43%	-$678K	﹤0.01%	310
2021 Q3	$1.73M	Sell	5,512 -8,522	-61%	-$2.53M	0.01%	307
2021 Q2	$5.24M	Sell	14,034 -2,542	-15%	-$1.25M	0.03%	254
2021 Q1	$14.3M	Buy	+16,576	New	+$14M	0.08%	177

Other funds holding VOR

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return

Gilder Gagnon Howe & Co's VOR Position: Q1 2022 in Review

Gilder Gagnon Howe & Co sold out of Vor Biopharma (VOR) in Q1 2022, closing a stake of 3,159 shares — an estimated $734K sold.

Gilder Gagnon Howe & Co first reported a position in VOR in Q1 2021 and held it in 4 quarters. The position peaked at $14.3M in Q1 2021. 58 funds tracked by Wall St. Rank hold VOR as of Q1 2022.

Gilder Gagnon Howe & Co reported no remaining Vor Biopharma position as of Q1 2022 after selling out during the quarter.
Gilder Gagnon Howe & Co sold 3,159 Vor Biopharma shares in Q1 2022, an estimated $734K.
Gilder Gagnon Howe & Co first reported a position in Vor Biopharma in Q1 2021 and held it in 4 quarters.
Gilder Gagnon Howe & Co's Vor Biopharma position peaked at $14.3M in Q1 2021.
58 funds tracked by Wall St. Rank held Vor Biopharma as of Q1 2022.

Based on Gilder Gagnon Howe & Co's 13F filing for Q1 2022, filed 16 May 2022.